



Figure 5. Clinical Question 4 “Group 3”



*Comment: There are insufficient data on the efficacy of HER2-targeted therapy in cases with HER2 ratio <2.0 in the absence of protein over-expression because such patients were not eligible for the first generation of adjuvant trastuzumab clinical trials. When concurrent IHC results are negative (0-1+), it is recommended that the specimen be considered HER2 negative.



COLLEGE of AMERICAN
PATHOLOGISTS

ASCO® Guidelines

www.asco.org/breast-cancer-guidelines © 2018 by the American Society of Clinical Oncology and College of American Pathologists. All rights reserved

This algorithm is derived from recommendations in Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. This is a tool based on an ASCO and CAP guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.